Summary:
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Efficacy and Pharmacodynamics of drug Administered Subcutaneously in Adult Patients with Persistent Eosinophilic Asthma.
Criteria:The patient has a diagnosis of asthma for at least 6 months as defined by the National Institutes of Health (NIH) and has been stable without exacerbation or change in medications for at least 3 months. The patient has an absolute blood eosinophil count ≥300 cells/μL demonstrated during the screening period. The patient is able to provide diary entries daily using a handheld device at home and also come into clinic on visit days to provide blood and perform spirometry.
Qualified Participants May Receive:
Each qualified participant will receive $60 for their time for each visit to the clinic (Total of 10 clinic visits completed in about 8 months time).